Profile data is unavailable for this security.
About the company
Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. The Company is engaged in providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers a number of technologies for viral vector manufacturing, including a fourth-generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. Its AAV platform, which offers a proprietary plug and play dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.
- Revenue in GBP (TTM)151.21m
- Net income in GBP-37.07m
- Incorporated1996
- Employees900.00
- LocationOXBWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
- Phone+44 186 578 3000
- Fax+44 186 578 3001
- Websitehttps://www.oxb.com/
Mergers & acquisitions
| Acquired company | OXB:LSE since announced | Transaction value |
|---|---|---|
| RTP Operating LLC-Gene Therapy Viral Vector Manufacturing Facility | 0.78% | 4.50m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Philogen SpA | 68.46m | 39.93m | 539.17m | 193.00 | 18.64 | 6.78 | 12.40 | 7.88 | 1.14 | 1.14 | 1.96 | 3.13 | 0.5961 | 5.65 | 21.87 | 430,158.50 | 34.77 | 0.7964 | 40.11 | 0.8907 | 74.04 | 58.86 | 58.33 | 3.70 | 5.52 | -- | 0.0837 | -- | 219.91 | 42.46 | 835.14 | 100.38 | 10.46 | -- |
| Basilea Pharmaceutica AG Allschwil | 222.94m | 38.60m | 687.54m | 189.00 | 18.25 | 5.17 | 17.04 | 3.08 | 2.95 | 2.95 | 16.98 | 10.41 | 0.861 | 1.48 | 20.78 | 1,229,524.00 | 14.91 | 11.57 | 18.09 | 17.51 | 83.08 | 82.84 | 17.32 | 14.94 | 4.68 | 24.70 | 0.3709 | -- | 11.43 | 12.73 | -48.14 | -- | 4.79 | -- |
| Valneva SE | 151.94m | 14.61m | 701.84m | 700.00 | -- | -- | -- | 4.62 | -0.375 | -0.375 | -- | -- | -- | -- | -- | 251,366.90 | -- | -14.46 | -- | -23.62 | 9.62 | 34.12 | 9.62 | -34.54 | -- | 1.84 | -- | -- | 10.32 | 6.09 | 87.93 | -- | 8.60 | -- |
| Gubra A/S | 306.96m | 196.80m | 749.14m | 269.00 | -- | 5.61 | -- | 2.44 | -4.42 | -4.42 | 161.57 | 70.16 | 2.73 | -- | 62.03 | 9,802,271.00 | 174.97 | 65.69 | 191.26 | 79.14 | 4.11 | 87.02 | 64.11 | 47.21 | -- | 20.13 | 0.0857 | -- | 892.25 | 72.57 | 4,731.94 | 166.01 | 21.62 | -- |
| Oxford BioMedica plc | 151.21m | -37.07m | 796.56m | 900.00 | -- | 21.37 | -- | 5.27 | -0.3539 | -0.3539 | 1.46 | 0.3084 | 0.6556 | 5.25 | 4.25 | 175,626.00 | -16.95 | -20.23 | -23.87 | -25.48 | 44.12 | 49.36 | -25.85 | -45.03 | 1.67 | -4.81 | 0.7631 | -- | 43.84 | 14.99 | 72.58 | -- | -21.89 | -- |
| Evotec SE | 657.77m | -138.26m | 874.36m | 4.79k | -- | 1.25 | -- | 1.33 | -0.8955 | -0.8955 | 4.26 | 4.50 | 0.4019 | 20.15 | 5.17 | 156,687.00 | -8.45 | -2.40 | -10.41 | -2.87 | 10.82 | 21.49 | -21.02 | -6.78 | 2.03 | -2.54 | 0.3772 | -- | 1.99 | 12.29 | -133.67 | -- | 32.89 | -- |
| Idorsia Ltd | 223.06m | -113.15m | 913.10m | 938.00 | -- | -- | -- | 4.09 | -0.6593 | -0.6593 | 1.06 | -4.88 | 0.4807 | 0.3793 | 796.27 | -- | -24.38 | -48.63 | -53.54 | -61.12 | 86.49 | -- | -50.72 | -526.39 | 0.8345 | -6.02 | 31.03 | -- | -26.17 | 36.41 | 11.47 | -- | -1.08 | -- |
| Inventiva SA | 11.84m | -270.53m | 928.50m | 84.00 | -- | -- | -- | 78.44 | -3.62 | -3.62 | 0.1543 | -0.064 | 0.1247 | -- | 2.35 | 124,871.60 | -284.55 | -80.43 | -555.93 | -122.98 | -- | -- | -2,282.71 | -989.96 | -- | -0.5041 | 1.18 | -- | -47.37 | 5.62 | -66.82 | -- | 19.61 | -- |
| Kuros Biosciences AG | 84.90m | -4.53m | 1.03bn | 122.00 | -- | 17.32 | -- | 12.09 | -0.1236 | -0.1369 | 2.29 | 1.58 | 1.16 | 1.75 | 7.11 | 725,422.60 | -6.18 | -10.85 | -7.79 | -12.28 | 83.57 | 84.11 | -5.33 | -31.80 | 1.74 | -0.4702 | 0.0655 | -- | 129.67 | 101.59 | 62.67 | -- | 60.45 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Briarwood Chase Management LLCas of 26 Jan 2026 | 18.64m | 15.44% |
| Natixis Investment Managers International SAas of 02 Feb 2026 | 11.51m | 9.53% |
| M&G Investment Management Ltd.as of 14 Jan 2026 | 5.69m | 4.72% |
| Hargreaves Lansdown Asset Management Ltd.as of 21 Mar 2025 | 3.48m | 2.88% |
| Threadneedle Asset Management Ltd.as of 13 Feb 2026 | 2.98m | 2.47% |
| Charles Schwab Investment Management, Inc.as of 02 Feb 2026 | 2.63m | 2.18% |
| BlackRock Investment Management (UK) Ltd.as of 25 Feb 2026 | 2.57m | 2.13% |
| Lansdowne Partners (UK) LLPas of 26 Jan 2026 | 2.43m | 2.01% |
| Liontrust Investment Partners LLPas of 19 Feb 2026 | 2.24m | 1.86% |
| Banque Pictet & Cie SAas of 02 Feb 2026 | 2.07m | 1.72% |
